Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | LYN | P07948 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3996010 | 0.81 | CYP2A6 (0.35) | PRKCQPRKCDALDH1A1LYNRAB9A | |
| SCHEMBL3995643 | 0.81 | EGFR (0.33) | EGFRERBB2TTRALBPRKCQ | |
| SCHEMBL4941463 | 0.81 | PRKCQ (0.31) | PRKCQPRKCDLYNRAB9A | |
| SCHEMBL30727714 | 0.81 | CYP2A6 (0.35) | PRKCQPRKCDALDH1A1LYNRAB9A | |
| SCHEMBL7481280 | 0.71 | HPGD (0.34) | KDM4EALDH1A1MAPT | |
| SCHEMBL3998036 | 0.70 | AURKA (0.37) | PRKCQMAP2K1KDM4EALDH1A1 | |
| SCHEMBL31674353 | 0.70 | AURKA (0.37) | PRKCQMAP2K1KDM4EALDH1A1 | |
| SCHEMBL19126689 | 0.70 | APP (0.40) | MAP2K1KDM4E | |
| SCHEMBL23501074 | 0.68 | SRC (0.42) | EGFRERBB2MAP2K1 | |
| SCHEMBL4348554 | 0.68 | ALDH1A1 (0.37) | ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937690-A1 | THIENO[2,3-B]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20080076926-A1 | Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles | WYETH | 2008-03-27 | — | — | US | disclosed |
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2007-04-12 | — | — | US | disclosed |
| WO-2007038519-A1 | THIENO[2,3-B]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076926-A1 | Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles | MAP4K2, MAP4K1, MAP4K3 | EGFR 1467/4885ERBB2 320/4885TTR 1681/4885 |
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | MAP4K2, CNKSR1, MAP3K1 | EGFR 1481/4885ERBB2 229/4885TTR 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.